Cargando…
Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis
Hypertrophic cardiomyopathy (HCM) is a clinically and genetically heterogeneous disorder but data on survival rates are still conflicting and have not so far been quantitatively reviewed. The aim of this study is to conduct a meta-analysis of cohort studies to assess pooled survival rates and progno...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607340/ https://www.ncbi.nlm.nih.gov/pubmed/28931939 http://dx.doi.org/10.1038/s41598-017-12289-4 |
_version_ | 1783265278930452480 |
---|---|
author | Liu, Qun Li, Diandian Berger, Alan E. Johns, Roger A. Gao, Li |
author_facet | Liu, Qun Li, Diandian Berger, Alan E. Johns, Roger A. Gao, Li |
author_sort | Liu, Qun |
collection | PubMed |
description | Hypertrophic cardiomyopathy (HCM) is a clinically and genetically heterogeneous disorder but data on survival rates are still conflicting and have not so far been quantitatively reviewed. The aim of this study is to conduct a meta-analysis of cohort studies to assess pooled survival rates and prognostic factors for survival in patients with HCM. Nineteen studies were included representing 12,146 HCM patients. The pooled 1-, 3-, 5- and 10-year survival rates were 98.0%, 94.3%, 82.2% and 75.0%, respectively. Among patients with HCM, age, NYHA functional class, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickness and obstruction were significant prognostic factors for cardiovascular death. For sudden cardiac death, FHSD, nsVT, and obstruction showed significant predictive values. Moreover, estimation of population attributable risk (PAR) suggested that nsVT was the strongest predictor for cardiovascular death (13.02%, 95% CI 3.60–25.91%), while left ventricular outflow tract obstruction/mid-ventricular obstruction (LVO/MVO) was the strongest predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72–20.42% and 16.44%, 95% CI 7.45–31.55%, respectively). These risk factors may thus be useful for identifying HCM patients who might benefit from early diagnosis and therapeutic interventions. |
format | Online Article Text |
id | pubmed-5607340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-56073402017-09-24 Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis Liu, Qun Li, Diandian Berger, Alan E. Johns, Roger A. Gao, Li Sci Rep Article Hypertrophic cardiomyopathy (HCM) is a clinically and genetically heterogeneous disorder but data on survival rates are still conflicting and have not so far been quantitatively reviewed. The aim of this study is to conduct a meta-analysis of cohort studies to assess pooled survival rates and prognostic factors for survival in patients with HCM. Nineteen studies were included representing 12,146 HCM patients. The pooled 1-, 3-, 5- and 10-year survival rates were 98.0%, 94.3%, 82.2% and 75.0%, respectively. Among patients with HCM, age, NYHA functional class, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickness and obstruction were significant prognostic factors for cardiovascular death. For sudden cardiac death, FHSD, nsVT, and obstruction showed significant predictive values. Moreover, estimation of population attributable risk (PAR) suggested that nsVT was the strongest predictor for cardiovascular death (13.02%, 95% CI 3.60–25.91%), while left ventricular outflow tract obstruction/mid-ventricular obstruction (LVO/MVO) was the strongest predictor for all-cause death and sudden cardiac death (10.09%, 95% CI 4.72–20.42% and 16.44%, 95% CI 7.45–31.55%, respectively). These risk factors may thus be useful for identifying HCM patients who might benefit from early diagnosis and therapeutic interventions. Nature Publishing Group UK 2017-09-20 /pmc/articles/PMC5607340/ /pubmed/28931939 http://dx.doi.org/10.1038/s41598-017-12289-4 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Liu, Qun Li, Diandian Berger, Alan E. Johns, Roger A. Gao, Li Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
title | Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
title_full | Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
title_fullStr | Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
title_full_unstemmed | Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
title_short | Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
title_sort | survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607340/ https://www.ncbi.nlm.nih.gov/pubmed/28931939 http://dx.doi.org/10.1038/s41598-017-12289-4 |
work_keys_str_mv | AT liuqun survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis AT lidiandian survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis AT bergeralane survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis AT johnsrogera survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis AT gaoli survivalandprognosticfactorsinhypertrophiccardiomyopathyametaanalysis |